Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - oxaliplatin, quantity: 100 mg - injection, concentrated - excipient ingredients: water for injections; lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - oxaliplatin, quantity: 50 mg - injection, concentrated - excipient ingredients: water for injections; lactose monohydrate - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour; treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - oxaliplatin, quantity: 5 mg/ml - injection, concentrated - excipient ingredients: succinic acid; sodium hydroxide; water for injections - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of advanced colorectal cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - oxaliplatin, quantity: 5 mg/ml - injection, concentrated - excipient ingredients: succinic acid; water for injections; sodium hydroxide - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for: - adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour. - treatment of advanced colorectal cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - oxaliplatin 100mg;   - powder for infusion - 100 mg - active: oxaliplatin 100mg   excipient: lactose - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour;

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - oxaliplatin 50mg;   - powder for infusion - 50 mg - active: oxaliplatin 50mg   excipient: lactose - oxaliplatin, in combination with fluorouracil and folinic acid, is indicated for adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour;

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - oxaliplatin 100mg - powder for injection - 100 mg - active: oxaliplatin 100mg excipient: lactose - oxaliplatin, in combination with 5-fluorouracil and folinic acid, is indicated for: · adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - oxaliplatin 50mg - powder for injection - 50 mg - active: oxaliplatin 50mg excipient: lactose - oxaliplatin, in combination with 5-fluorouracil and folinic acid, is indicated for: · adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - oxaliplatin 5 mg/ml - solution for injection - 5 mg/ml - active: oxaliplatin 5 mg/ml excipient: water for injection - oxaliplatin, in combination with 5-fluorouracil and folinic acid, is indicated for: · adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour.

Israel - English - Ministry of Health

genmedix , israel - oxaliplatin - powder for solution for infusion - oxaliplatin 5 mg/ml - oxaliplatin - oxaliplatin in combination with 5 fluorouracil (5 fu) and folinic acid (fa) is indicated for: • adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of primary tumour. • treatment of metastatic colorectal cancer. oxaliplatin in combination with leucovorin, irinotecan and 5-fluorouracil is indicated for the first line treatment of patients with metastatic pancreatic adenocarcinoma (based on nccn guidelines, version 2.2014).